Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial entities : Otonomy, inc. save search
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
Published: 2022-08-01 (Crawled : 12:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: -74.57%
H: 16.16%
C: -21.27%
oto-313 trial results phase 2
AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting
Published: 2022-06-06 (Crawled : 17:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: 2.04%
H: 2.5%
C: -1.5%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 2.06%
H: 0.24%
C: -1.95%
agtc-501 treatment trial
Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
Published: 2022-05-04 (Crawled : 17:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: -1.2%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 0.48%
H: 1.8%
C: -4.96%
agtc-501 ongoing research positive phase 1
Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss
Published: 2022-04-20 (Crawled : 12:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: 0.92%
H: 15.45%
C: 4.09%
oto-413 trial positive results topline phase 2b
AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
Published: 2022-04-04 (Crawled : 21:00) - globenewswire.com
OTIC | $0.077
|
Health Technology
|
| O: -0.41%
H: 0.41%
C: -1.24%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 0.0%
H: 3.67%
C: 0.0%
ongoing trials research phase 1
Green Lights and Setbacks: Clinical Trial Updates for Feb. 21-25
Published: 2022-02-28 (Crawled : 15:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: -1.51%
H: 4.59%
C: 3.06%
trial set
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
Published: 2022-02-22 (Crawled : 13:30) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: 1.5%
H: 3.77%
C: -0.49%
oto-313 phase 2 trial enroll
AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
Published: 2022-01-11 (Crawled : 14:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: 3.32%
H: 0.0%
C: 0.0%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: 0.0%
enroll treatment
AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
OTIC | $0.077
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: 0.0%
ongoing phase 1 trial
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
OTIC | $0.077
|
Health Technology
|
| O: 0.0%
H: 3.45%
C: 0.0%
phase 1 results trial trial results phase 2
AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration
Published: 2021-09-28 (Crawled : 15:15) - agtc.com
OTIC | $0.077
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: -2.55%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 0.62%
H: 1.07%
C: -4.29%
ongoing phase 1 retina trials trial symposium
AGTC to Participate in Clinical Trials in Rare Diseases Conference Panel and Case Study
Published: 2021-09-09 (Crawled : 12:15) - agtc.com
OTIC | $0.077
|
Health Technology
|
| O: 0.0%
H: 1.33%
C: -0.67%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 1.49%
H: 2.35%
C: -0.29%
disease clinical trials trials trial conference rare
Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
Published: 2021-08-24 (Crawled : 13:15) - agtc.com
OTIC | $0.077
|
Health Technology
|
| O: 0.72%
H: 2.88%
C: 2.52%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 0.29%
H: 3.02%
C: 2.3%
eye children trial
AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene
Published: 2021-06-24 (Crawled : 12:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: -0.89%
H: 3.14%
C: 1.35%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 5.28%
H: 4.56%
C: -1.59%
ongoing clinical trials phase 1 trial phase 2
AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
Published: 2021-06-23 (Crawled : 21:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: 0.92%
H: 2.73%
C: 2.27%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 2.17%
H: 0.0%
C: -1.42%
ongoing clinical trials phase 1 trial conference
AGTC to Host Conference Call to Discuss Achromatopsia 12-Month Data in its Ongoing Phase 1/2 Clinical Trials
Published: 2021-06-23 (Crawled : 21:00) - agtc.com
OTIC | $0.077
|
Health Technology
|
| O: -0.89%
H: 3.14%
C: 1.35%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 5.28%
H: 4.56%
C: -1.59%
ongoing clinical trials phase 1 trial conference phase 2 phase 3
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss
Published: 2021-06-15 (Crawled : 12:00) - globenewswire.com
OTIC | $0.077
|
Health Technology
|
| O: 2.13%
H: 2.92%
C: -1.67%
phase 1 expansion trial hearing loss phase 3 phase 2
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
Published: 2021-03-25 (Crawled : 13:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: -1.88%
H: 2.3%
C: 0.0%
phase 2 trial
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
Published: 2021-02-22 (Crawled : 12:03) - globenewswire.com
OTIC | $0.077
|
Health Technology
|
| O: -49.54%
H: 23.53%
C: 10.29%
disease results phase 3 trial topline
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.